The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) hit a new 52-week high and has $190.02 target or 60.00% above today’s $118.76 share price. The 5 months bullish chart indicates low risk for the $10.97B company. The 1-year high was reported on Nov, 21 by Barchart.com. If the $190.02 price target is reached, the company will be worth $6.58B more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 338,694 shares traded hands. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 44.58% since April 19, 2016 and is uptrending. It has outperformed by 40.72% the S&P500.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Ratings Coverage
Out of 7 analysts covering IDEXX Laboratories (NASDAQ:IDXX), 3 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 43% are positive. IDEXX Laboratories has been the topic of 13 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The company was maintained on Monday, March 21 by Stifel Nicolaus. As per Friday, April 1, the company rating was initiated by CL King. Stifel Nicolaus maintained it with “Buy” rating and $80 target price in Thursday, October 29 report. The firm earned “Buy” rating on Thursday, July 23 by Canaccord Genuity. Feltl & Co upgraded the shares of IDXX in a report on Friday, July 24 to “Hold” rating. The stock has “Outperform” rating given by Credit Suisse on Wednesday, April 13. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, July 20. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) has “Outperform” rating given on Thursday, February 4 by Credit Suisse. As per Thursday, September 29, the company rating was reinitiated by Bank of America. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) earned “Market Perform” rating by Raymond James on Friday, August 28.
According to Zacks Investment Research, “IDEXX Laboratories, Inc. is a world leader in providing diagnostic, detection, and information products to the animal health industry as well as quality assurance products and services to the food and water industries.”
Insitutional Activity: The institutional sentiment decreased to 1.14 in 2016 Q2. Its down 0.20, from 1.34 in 2016Q1. The ratio dropped, as 27 funds sold all IDEXX Laboratories, Inc. shares owned while 123 reduced positions. 79 funds bought stakes while 122 increased positions. They now own 77.90 million shares or 5.94% less from 82.81 million shares in 2016Q1.
Next Fincl Incorporated has invested 0% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Blackrock Limited accumulated 509,227 shares or 0.02% of the stock. Moreover, Neuberger Berman Group Limited Company has 0.34% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 2.66M shares. Korea Inv Corporation last reported 105,500 shares in the company. Woodstock has 62,570 shares for 1.2% of their US portfolio. Weiss Multi accumulated 9,494 shares or 0.07% of the stock. City Holdg last reported 0% of its portfolio in the stock. Stephens Ar, a Arkansas-based fund reported 13,124 shares. M&T Bankshares has invested 0.01% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Kanaly Trust Company last reported 133 shares in the company. Aperio Gp Ltd Company owns 22,332 shares or 0.02% of their US portfolio. Plante Moran Fin Advisors Limited Liability last reported 45 shares in the company. Prudential Public Ltd Liability Co has invested 0% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Mutual Of America Cap Mgmt Ltd Liability last reported 67,082 shares in the company. Columbia Wanger Asset Limited Liability Corp reported 370,439 shares or 0.4% of all its holdings.
Insider Transactions: Since August 4, 2016, the stock had 0 insider buys, and 7 selling transactions for $19.47 million net activity. $4.31M worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was sold by AYERS JONATHAN W. 5,000 shares were sold by END WILLIAM T, worth $542,521. Another trade for 9,924 shares valued at $1.11 million was sold by JOHNSON BARRY C. $1.10M worth of shares were sold by HENDERSON REBECCA M on Thursday, August 25. Williams Michael J PhD sold $5.40 million worth of stock or 49,560 shares.
More notable recent IDEXX Laboratories, Inc. (NASDAQ:IDXX) news were published by: Prnewswire.com which released: “IDEXX Laboratories Announces Departure of Executive Vice President Michael …” on November 15, 2016, also Fool.com with their article: “Why IDEXX Laboratories, Inc. Reported Higher Today” published on August 02, 2016, Fool.com published: “IDEXX Laboratories, Inc. Sees More Growth Ahead” on May 02, 2016. More interesting news about IDEXX Laboratories, Inc. (NASDAQ:IDXX) were released by: Prnewswire.com and their article: “IDEXX Laboratories to Host 2016 Investor Day” published on August 08, 2016 as well as Prnewswire.com‘s news article titled: “IDEXX Welcomes Healthcare Technology Veteran Pat Venters as Chief Marketing …” with publication date: November 14, 2016.
IDXX Company Profile
IDEXX Laboratories, Inc., incorporated in 1983, develops, makes and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Firm operates through three divisions: diagnostic and information technology services and products for the veterinary market, which it refers to as the Companion Animal Group (CAG), water quality products (Water) and products for livestock and poultry health, which it refer to as Livestock and Poultry Diagnostics (LPD). It also operates two smaller divisions that consist of products for milk quality and safety (Dairy) and products for the human point-of-care medical diagnostics market (OPTI Medical). In November 2011, the Company acquired the research and diagnostic laboratory (RADIL) business of the College of Veterinary Medicine from the University of Missouri. In August 2013, IDEXX Laboratories, Inc. announced that it has acquired Madasa do Brasil Ltda.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.